Runben Biotechnology Balance Sheet Health
Financial Health criteria checks 5/6
Runben Biotechnology has a total shareholder equity of CN¥2.0B and total debt of CN¥1.3M, which brings its debt-to-equity ratio to 0.07%. Its total assets and total liabilities are CN¥2.1B and CN¥108.2M respectively. Runben Biotechnology's EBIT is CN¥256.2M making its interest coverage ratio -263.6. It has cash and short-term investments of CN¥132.4M.
Key information
0.07%
Debt to equity ratio
CN¥1.33m
Debt
| Interest coverage ratio | -263.6x |
| Cash | CN¥132.38m |
| Equity | CN¥1.96b |
| Total liabilities | CN¥108.21m |
| Total assets | CN¥2.07b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 603193's short term assets (CN¥1.8B) exceed its short term liabilities (CN¥105.4M).
Long Term Liabilities: 603193's short term assets (CN¥1.8B) exceed its long term liabilities (CN¥2.8M).
Debt to Equity History and Analysis
Debt Level: 603193 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 603193's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 603193's debt is well covered by operating cash flow (19433.8%).
Interest Coverage: 603193 earns more interest than it pays, so coverage of interest payments is not a concern.